Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Starling Oncology's free cash flow for the twelve months ending Jun 30, 2026 was -$3.29M. For fiscal 2025 it was -$27.79M. The highest annual figure on record is -$686.00K in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.79M | – |
| FY2024 | Dec 31, 2024 | -$30.33M | – |
| FY2023 | Dec 31, 2023 | -$40.88M | – |
| FY2022 | Dec 31, 2022 | -$67.29M | – |
| FY2021 | Dec 31, 2021 | -$35.53M | – |
| FY2020 | Dec 31, 2020 | -$686.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.26M | – |
| Q4 FY2025 | Dec 31, 2025 | $2.17M | -3.2% |
| Q3 FY2025 | Sep 30, 2025 | -$13.23M | -1183.9% |
| Q2 FY2025 | Jun 30, 2025 | -$11.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.32M | – |
| Q4 FY2024 | Dec 31, 2024 | $2.25M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$155.00K | – |